Solid forms of macrocyclic compounds, salts and formulations thereof, and methods of preparing and using the same
AssigneeKura Oncology, Inc.
InventorsRoger Paul Bakale, Kenneth K. Liu, Yun Shan, Xiufeng Sun, Patricia Andres, Song Chen, Yue Lu, Licheng Song, Catalina Ferrer, Ana Rita Neves
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to solid forms of Compound 1, or a pharmaceutically acceptable form thereof, a pharmaceutically acceptable salt of Compound 1, or pharmaceutically acceptable solvate thereof, pharmaceutical compositions comprising the same, methods of preparing the same, and methods of treating cancer dependent on a farnesylated protein, using the same.
Claims28
A solid form comprising Compound 1, or a pharmaceutically acceptable salt and/or a pharmaceutically acceptable solvate thereof:
- wherein the solid form is crystalline.
A solid form comprising a pharmaceutically acceptable solvate of Compound 1, or a pharmaceutically acceptable salt thereof:
- wherein:
- i) the pharmaceutically acceptable solvate is selected from the group consisting of:
- a hydrate, an iso-butyl acetate solvate, an iso-propyl acetate solvate, a tetrahydrofuran solvate, an acetone solvate, and an acetonitrile solvate, and combinations thereof;
- and
- ii) the pharmaceutically acceptable solvate comprises (a) the Compound 1 or the pharmaceutically acceptable salt thereof, and (b) a pharmaceutically acceptable solvent, solvent are present in a molar ratio in the range of about 2:1 to about 1:2.
Dependencies are inferred from the claim text.